
Innovative Molecules Offer Good News in the Fight Against HIV and Other Viral Infections Français
LAVAL, QC, July 3, 2025 /CNW/ - Innovative, nontoxic molecules developed by a research team at the Institut national de la recherche scientifique (INRS) could pave the way for new safe and effective antiviral therapies for prevention and treatment purposes. Are there natural compounds with antiviral properties, particularly against the human immunodeficiency virus (HIV) that causes AIDS?
Betulinic acid has long been recognized in medical and scientific communities for its antiviral potential. This molecule, found in various plants, is especially abundant in the bark of white birch trees—a common byproduct of the forestry industry. However, the use of betulinic acid and some of its derivatives in medicine has been limited by a major drawback: the molecules are poorly soluble in water. This limits their absorption by the body and complicates their use in medicine.
A discovery by INRS Professor Charles Gauthier 's team, part of the INRS-UQAC Joint Research Unit in Sustainable Health, could significantly unlock the potential of this molecule. Their findings * were recently published in Chemistry – A European Journal.
Creating a Promising and Novel Molecule
In their research, Professor Gauthier's team studied two natural molecules: betulinic acid and echinocystic acid. Both belong to a family of compounds known as triterpenes and share a similar chemical structure.
The researchers chemically modified these molecules using a novel, controlled method by attaching a specific sugar called Lewis X. This sugar is structurally similar to those that define human blood groups. The modification resulted in new chimeric compounds known as "saponins."
These saponins had never been described in scientific literature before. They offer several advantages for potential antiviral use: they are significantly more water-soluble than triterpenes, they dissolve well in biological environments, and unlike similar substances that can be toxic, they are safe for human cells and mice.
Most importantly, they effectively block HIV activity. The team observed that saponins prevent the virus from using certain carbohydrate-specific proteins, known as Lewis-binding proteins, found on immune cells called DC-SIGN and L-SIGN, to spread to CD4+ cells, the main targets of HIV.
"Our results show that these are among the most potent monovalent inhibitors ever identified for blocking this HIV transfer mechanism, even when used at very low concentrations," explains INRS Professor Gauthier, who specializes in chemistry of carbohydrates and natural products. He is also a member of the Pasteur Network.
HIV, Ebola disease, dengue fever, coronaviruses: the potential is vast
These chimeric molecules capable of blocking viral entry into immune cells—a critical step in infection—are a first of their kind. Saponins could serve as a foundation for developing broad-spectrum antiviral agents that block infection at the earliest stage, such as during sexual transmission of HIV.
"While it's known that human breast milk contains oligosaccharides that protect infants from HIV infection during early breastfeeding, we are the first to demonstrate that saponins can inhibit HIV entry via DC-SIGN and L-SIGN receptors," says doctoral student in biology at INRS and lead author Oscar Javier Gamboa Marin.
"Despite progress in this field, very few studies have focused on inhibiting DC-SIGN and L-SIGN using Lewis-type carbohydrates," he adds.
Another promising feature of saponins is their ability to spontaneously form structures called micelles or to integrate into liposomes. This could further enhance their antiviral effectiveness, particularly through improved targeting of virus-infected cells, and holds out promising research potential.
Moreover, since DC-SIGN and L-SIGN proteins are also exploited by other dangerous viruses such as Ebola, dengue, and SARS-CoV-2, saponins open new avenues for developing broad-spectrum antiviral agents against these diseases.
About the studies*
The article entitled Lewis-X-Containing Triterpenoid Saponins Inhibit DC-SIGN- and L-SIGN-Mediated Transfer of HIV-1 Infection was co-authored by Oscar Javier Gamboa Marin, Kurtis Ng, Nitish Verma, Assi Gérard Flavien Yapi, Ralph Pantophlet, and Charles Gauthier.
The article entitled Immunological and Toxicological Assessment of Triterpenoid Saponins Bearing Lewis-X- and QS-21-Based Trisaccharides was co-authored by Oscar Javier Gamboa Marin, Yasmine Adda-Bouchard, Balla Sylla, Nitish Verma, Tania Charpentier, Maya Huber, Guillaume Lopez, André Pichette, Alain Lamarre, and Charles Gauthier.
This work was made possible thanks to the support of the Natural Sciences and Engineering Research Council of Canada, the Fonds de recherche du Québec, the Armand-Frappier Foundation, and the Swine and Poultry Infectious Diseases Research Center.
INRS is an academic institution dedicated exclusively to graduate research and training in strategic sectors in Quebec. Since 1969, as per its mission, it has actively contributed to Quebec's economic, social, and cultural development. INRS ranks first in Quebec in research intensity. It is made up of five interdisciplinary research and training centres located in Quebec City, Montreal, Laval, and Varennes, and Charlevoix, which focus their efforts on strategic sectors: water, earth, and environment (Eau Terre Environnement Research Centre); energy, materials, and telecommunications (Énergie Matériaux Télécommunications Research Centre); urbanization, culture, and society (Urbanisation Culture Société Research Centre); and health and biotechnology (Armand-Frappier Santé Biotechnologie Research Centre), and Ruralités Durables Research Centre (a center currently under development). Its community includes nearly 1,500 members, including students, postdoctoral fellows, faculty members, and staff.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
6 hours ago
- Cision Canada
Enoki Mushroom recalled due to Listeria monocytogenes
OTTAWA, ON, Aug. 12, 2025 /CNW/ - Product: Enoki Mushroom Issue: Food - Microbial contamination - Listeria Distribution Nova Scotia Ontario Quebec Online link SOURCE Canadian Food Inspection Agency (CFIA)


Cision Canada
9 hours ago
- Cision Canada
BQE Water Integrates Aquatic Toxicology Services into its Core Competencies
VANCOUVER, BC, Aug. 12, 2025 /CNW/ - BQE Water Inc. (TSXV: BQE), a leader in the treatment and management of mine impacted waters, is pleased to announce that it is making a strategic investment into the integration of aquatic toxicology services into its existing business and suite of core competencies. This expansion is underpinned and made possible by a team of senior aquatic toxicologists including James Elphick, Dr Ebrahim (Ebi) Lari, and Josh Baker joining the BQE Water team. The investment includes the establishment of an aquatic toxicology laboratory as well as development of in-house resources to maintain BQE Water's leadership in the area of production of clean mine water. The goal of this investment is to improve the services offered by BQE Water to its clients, specifically: To reduce timelines and costs associated with implementing remedies to toxicity occurring in mine waters by having a strong in-house multidisciplinary team capable of evaluating causes of toxicity, performing all required testing, and designing remedies. To consider establishment of science-based site-specific water quality benchmarks holistically, including costs and risks of water treatment to optimize water quality from early project stages. To be in a unique position to provide guarantees to clients with respect to effluent toxicity as part of plant operations services. David Kratochvil, the President and CEO of BQE Water, stated, "Over the last few years, we have identified aquatic toxicology services as an area of strategic interest for the Company. These services are not only perfectly complementary to our existing suite of services, but they also offer the potential for accelerated growth in our water treatment business. We are pleased to welcome top calibre aquatic toxicologists to help us expand and grow BQE Water while improving service offering to our clients." James Elphick commented, "Having spent 30 years performing applied research and testing to advance the science of aquatic toxicology and help clients gain an understanding of causes of toxicity and interaction of toxicants with water quality conditions, I am excited to have the opportunity to align this interest with a water solutions focused organization that partners with clients to deliver clean water production services. Approaching toxicity identification investigations and addressing gaps in the understanding of toxicant behaviour from a practical treatment perspective provides a unique service that will address ecological risks and reduce timelines for implementing the right remedies. While the plan is for the new BQE Water's toxicity testing laboratory to be fully accredited, the primary purpose of the laboratory is to support the Company's water treatment business and focus on investigative type of work rather than building a capacity for processing a high volume of samples for routine bioassays." About the Team of Senior Aquatic Toxicologists James Elphick, Dr. Ebi Lari and Josh Baker bring substantial experience in the field of aquatic toxicology and understanding of causes of toxicity in mine water, including having been instrumental in developing water quality benchmarks for contaminants of concern at mine sites, such as selenium, nickel, copper, sulphate, chloride, nitrate, ammonia, and in researching novel approaches to understanding interactions of toxicants with water quality conditions. About BQE Water BQE Water is a service provider specializing in water treatment and management for metals mining, smelting and refining. We are helping to transform the way the industry thinks about water in the context of natural resource projects by offering services and expertise which enables more sustainable water management practices and improved overall project performance at reduced risk. BQE Water invests in innovation and has developed unique intellectual property through the commercialization of several new technologies at mine sites around the world for organizations including Glencore, Jiangxi Copper, Freeport-McMoRan and the US EPA. BQE Water is headquartered in Vancouver, Canada and trades on the TSX Venture Exchange under the symbol BQE. Visit for more information. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION Certain information contained herein may not be based on historical fact and therefore constitutes "forward-looking information" under applicable Canadian securities legislation. This includes without limitation statements containing the words "plan", "expect", "project", "estimate", "intend", "believe", "anticipate", "may", "will" and other similar words or expressions. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's dependence on key personnel and contracts, uncertainty with respect to the profitability of the Company's technologies, competition, technology risk, the Company's ability to protect its intellectual property and proprietary information, fluctuations in commodity prices, currency risk, environmental regulation and the Company's ability to manage growth and other factors described in the Company's filings with the Canadian securities regulators at (including without limitation the factors described in the section entitled "Risks and Uncertainties" in the Company's MD&A for the year ended December 31, 2024). Given these risks and uncertainties, the reader is cautioned not to place undue reliance on forward-looking statements. All forward-looking information contained herein is based on management's current expectations and the Company undertakes no obligation to revise or update such forward-looking information to reflect subsequent events or circumstances, except as required by law. SOURCE BQE Water Inc.


Cision Canada
16 hours ago
- Cision Canada
Media Advisory - STRATOS 2025: Canadian innovations to be tested in space-like environment Français
LONGUEUIL, QC, Aug. 12, 2025 /CNW/ - From August 10 to September 10, 12 Canadian payloads will be launched from the Timmins Stratospheric Balloon Base to test new technologies, conduct science experiments and take measurements as part of the Strato-Science 2025 campaign. The campaign is part of STRATOS, the Canadian Space Agency's (CSA) stratospheric balloon program. Created in 2012 in collaboration with France's Centre national d'études spatiales, STRATOS gives Canadian researchers and industry a unique opportunity to test and validate new space technologies in a space-like environment, while helping train the next generation of space experts. Since opening in 2013, the Timmins base has supported nearly 100 experiments and involved over 500 researchers and students from across Canada. Stratospheric balloons offer a cost-effective and rapid platform for advancing space science and technology. Media interested in interviews with CSA experts may contact the Media Relations Office.